Colton Groome Financial Advisors LLC bought a new position in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) during the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 3,121 shares of the biopharmaceutical company stock, valued at approximately $ 228,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mizuho Securities Co. Ltd. lifted its stake in shares of Bristol-Myers Squibb by 239.0% in the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company stock valued at $ 25,000 after purchasing an additional 239 shares during the period. Steward Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 29,000. Horan Securities Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 29,000. Guardian Wealth Management Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 32,000. Finally, Leverty Financial Group LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $ 37,000. 73.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently commented on BMY shares. Raymond James lowered Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and issued a $ 90.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, June 3rd. StockNews.com began coverage on Bristol-Myers Squibb in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Barclays boosted their price target on Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a report on Monday, May 2nd. Finally, Guggenheim boosted their price target on Bristol-Myers Squibb from $ 72.00 to $ 80.00 in a report on Monday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Moderate Buy” and an average target price of $ 74.27.
Bristol-Myers Squibb stock opened at $ 78.88 on Monday. Bristol-Myers Squibb has a 12 month low of $ 53.22 and a 12 month high of $ 79.00. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 1.18. The business’s 50 day simple moving average is $ 75.96 and its 200 day simple moving average is $ 70.30. The company has a market cap of $ 167.94 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 1.67 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last posted its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $ 1.96 EPS for the quarter, beating the consensus estimate of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $ 11.65 billion for the quarter, compared to the consensus estimate of $ 11.34 billion. During the same quarter in the prior year, the business earned $ 1.74 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 7.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Friday, July 1st will be paid a $ 0.54 dividend. The ex-dividend date of this dividend is Thursday, June 30th. This represents a $ 2.16 annualized dividend and a yield of 2.74%. Bristol-Myers Squibb’s payout ratio is 76.60%.
In related news, CEO Giovanni Caforio sold 30,000 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the sale, the chief executive officer now owns 551,104 shares in the company, valued at $ 40,803,740.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sandra Leung sold 65,000 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares in the company, valued at approximately $ 23,113,076.03. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company stock.
Bristol-Myers Squibb Company Profile: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Further Reading:
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.
.